A Phase 3 interventional study of bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy) and Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Allergan. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-10.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing bimatoprost in Glaucoma, Open-Angle — 2 open to participants now, 2 under way, 1 of them phase 3. Bimatoprost · Glaucoma, Open-Angle.
Among the 29 studies testing bimatoprost in Glaucoma, Open-Angle, this one is the 13th largest by enrollment, is one of 6 that started in 2011, is one of 9 in phase 3, and was the 5th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →2 of the 29 studies testing bimatoprost in Glaucoma, Open-Angle are open now, in 2 countries. Recruiting first, the newest first:
YS Life Science Co., Ltd. · Sites in United States, India
Ages 18+
Amneal Pharmaceuticals, LLC · Sites in United States
Ages 18+
By country, each count listing its studies:
Bimatoprost: first FDA approval 2001 (LUMIGAN), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 9 · Phase 4 12
First in 2007; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 192 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 169 across the 29 interventional studies. Of the 27 that completed or were terminated, 23 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 29 have an industry lead sponsor. The 7 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
58 studies in Glaucoma, Open-Angle by AbbVie: 1 open now, 3 under way, 1 of them phase 3. Of 54 finished, 42 (78%) have results posted.
Among the 58 studies in Glaucoma, Open-Angle by AbbVie, this one is the 14th largest by enrollment of the 34 interventional ones that give a count, is one of 8 that started in 2011, is one of 12 in phase 3, and was the 15th registered.
AbbVie’s Glaucoma, Open-Angle studies by the year they started, since 1999.
1 of the studies testing bimatoprost in Glaucoma, Open-Angle that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07661329Phase 3YS Life Science Co., Ltd.A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies testing bimatoprost in Glaucoma, Open-Angle, from their registry updates:
Among AbbVie’s 58 in Glaucoma, Open-Angle:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
Drug: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)
Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
Drug: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
Drug pages: Bimatoprost · Brimonidine · Timolol
One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
Also known as: COMBIGAN®
Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12
IOP is a measurement of the fluid pressure inside the eye. For each eye, the IOP was either the average of 2 measurements, or, if a third measurement was required, the median of the 3 measurements. The worse eye was determined based on the IOP results at Baseline. The mean worse eye IOP was the average of the IOP measurements of the worse eye at hours 0 and 2 at week 12. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 12
Change From Baseline in Mean Worse Eye IOP
IOP is a measurement of the fluid pressure inside the eye. For each eye, the IOP was either the average of 2 measurements, or, if a third measurement was required, the median of the 3 measurements. The worse eye was determined based on the IOP results at Baseline. The mean worse eye IOP was the average of the IOP measurements of the worse eye at hours 0 and 2 at each visit. A negative change from Baseline indicated improvement.
Time frame: Baseline, Weeks 1, 2, 4 and 8
Mean Worse Eye IOP
IOP is a measurement of the fluid pressure inside the eye. For each eye, the IOP was either the average of 2 measurements, or, if a third measurement was required, the median of the 3 measurements. The worse eye was determined based on the IOP results at Baseline. The mean worse eye IOP was the average of the IOP measurements of the worse eye at hours 0 and 2 at each time-point.
Time frame: Weeks 1, 2, 4, 8 and 12
| Milestone | Triple Combination Therapy | Combigan® |
|---|---|---|
| Started | 94 | 98 |
| Completed | 86 | 89 |
| Not completed | 8 | 9 |
| Withdrew: Adverse event | 5 | 4 |
| Withdrew: Lost to follow-up | 2 | 4 |
| Withdrew: Personal reasons | 1 | 1 |
IOP is a measurement of the fluid pressure inside the eye. For each eye, the IOP was either the average of 2 measurements, or, if a third measurement was required, the median of the 3 measurements. The worse eye was determined based on the IOP results at Baseline. The mean worse eye IOP was the average of the IOP measurements of the worse eye at hours 0 and 2 at week 12. A negative change from Baseline indicated improvement.
| mmHg | Triple Combination Therapy | Combigan® |
|---|---|---|
| Baseline (n=93,95) | 24.62 ± 2.475 | 25.12 ± 2.178 |
| Change from Baseline at Week 12 (n=93,94) | -10.03 ± 2.661 | -9.18 ± 2.566 |
IOP is a measurement of the fluid pressure inside the eye. For each eye, the IOP was either the average of 2 measurements, or, if a third measurement was required, the median of the 3 measurements. The worse eye was determined based on the IOP results at Baseline. The mean worse eye IOP was the average of the IOP measurements of the worse eye at hours 0 and 2 at each visit. A negative change from Baseline indicated improvement.
| mmHg | Triple Combination Therapy | Combigan® |
|---|---|---|
| Baseline (n=93,95) | 24.62 ± 2.475 | 25.12 ± 2.178 |
| Change from Baseline at Week 1 (n=91,89) | -10.18 ± 3.149 | -8.90 ± 3.044 |
| Change from Baseline at Week 2 (n=88,93) | -10.40 ± 2.802 | -9.06 ± 2.925 |
| Change from Baseline at Week 4 (n=86,90) | -10.06 ± 2.793 | -9.21 ± 2.306 |
| Change from Baseline at Week 8 (n=88,89) | -9.77 ± 2.852 | -9.02 ± 2.869 |
IOP is a measurement of the fluid pressure inside the eye. For each eye, the IOP was either the average of 2 measurements, or, if a third measurement was required, the median of the 3 measurements. The worse eye was determined based on the IOP results at Baseline. The mean worse eye IOP was the average of the IOP measurements of the worse eye at hours 0 and 2 at each time-point.
| mmHg | Triple Combination Therapy | Combigan® |
|---|---|---|
| Week 1 (n=91,90) | 14.43 ± 2.785 | 16.23 ± 2.968 |
| Week 2 (n=88,95) | 14.05 ± 2.634 | 16.08 ± 2.726 |
| Week 4 (n=86,92) | 14.38 ± 2.587 | 15.96 ± 2.705 |
| Week 8 (n=88,91) | 14.68 ± 2.709 | 16.11 ± 2.935 |
| Week 12 (n=86,88) | 14.43 ± 2.344 | 15.92 ± 2.867 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Triple Combination Therapy | — | 3/93 (3.2%) | 57/93 (61.3%) |
| Combigan® | — | 0/98 (0%) | 25/98 (25.5%) |
| Event | Triple Combination Therapy | Combigan® |
|---|---|---|
| BradycardiaCardiac disorders | 1/93 | 0/98 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/93 | 0/98 |
| PyomyositisInfections and infestations | 1/93 | 0/98 |
| Pituitary tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/93 | 0/98 |
| Event | Triple Combination Therapy | Combigan® |
|---|---|---|
| Conjunctival hyperaemiaEye disorders | 22/93 | 4/98 |
| Eye irritationEye disorders | 13/93 | 4/98 |
| Dry eyeEye disorders | 10/93 | 2/98 |
| SomnolenceNervous system disorders | 5/93 | 8/98 |
| Eye pruritusEye disorders | 6/93 | 2/98 |
| Visual field defectNervous system disorders | 5/93 | 5/98 |
| Age, Customized(Participants) | Triple Combination Therapy | Combigan® | Total |
|---|---|---|---|
| ≤65 years | 67 | 74 | 141 |
| >65 years | 27 | 24 | 51 |
| Sex: Female, Male(Participants) | Triple Combination Therapy | Combigan® | Total |
|---|---|---|---|
| Female | 78 | 73 | 151 |
| Male | 16 | 25 | 41 |
The record gives a start of Mar 2011, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bimatoprost · Brimonidine · Timolol